



The 9th International Electronic Conference on Medicinal Chemistry (ECMC 2023)

01–30 November 2023 | Online

7 α -acetoxy-6 β -hydroxyroyleanone as lead compound: from extraction optimization to hybrid nanoparticles for breast cancer therapy

Chaired by **Dr. Alfredo Berzal-Herranz**
and **Prof. Dr. Maria Emília Sousa**



pharmaceuticals



Vera M.S. Isca^{1,2}, **Gabriel Bangay**^{1,3}, **Ana C. Matos**⁴, **João Morais**⁴, **Ana S. Viana**⁵,
Catarina P. Reis², **Catarina Pereira-Leite**¹, **Lucília Saraiva**⁴, **Carlos A.M Afonso**³,
Patrícia Rijo^{1,2,*}

¹ CBIOS – Universidade Lusófona's Research Center for Biosciences & Health Technologies, Lisbon, Portugal

² Research Institute for Medicines (iMED.Ulisboa), Faculdade de Farmácia, Universidade de Lisboa, Portugal

³ Universidad de Alcalá de Henares. Facultad de Farmacia, Departamento de Ciencias Biomédicas (Área de Farmacología; Nuevos agentes antitumorales, Acción tóxica sobre células leucémicas. Alcalá de Henares, Madrid, España

⁴ LAQV/REQUIMTE, Laboratório de Microbiologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Portugal



⁵ Centro de Química Estrutural, Faculdade de Ciências da Universidade de Lisboa, Portugal

* Corresponding author: patricia.rijo@ulusofona.pt



7 α -acetoxy-6 β -hydroxyroyleanone as drug lead: from extraction optimization to hybrid nanoparticles for breast cancer therapy

Graphical Abstract






Abstract: Breast cancer is the most prevalent cancer worldwide. *Plectranthus* spp. have been used in traditional medicine for various ailments, including cancer, and its bioactive components have been investigated for their potential anticancer effects. In particular, the compound 7 α -acetoxy-6 β hydroxyroyleanone (Roy, **1**) displayed promising antiproliferative activity against several cancer cell lines. However, Roy **1** is highly hydrophobic and consequently has low water solubility, limiting its therapeutic use. Nanoformulations offer a potential solution. Accordingly, Roy **1** was investigated as a lead compound for the development of new antitumoral drugs through extraction optimization from *P. grandidentatus*, study of reactivity, evaluation of aqueous stability, and synthesis of Roy **1** gold nanoparticles (NPs). The acetonitrile ultrasound assisted extraction method was optimized by performing three cycles of 30 minutes each, which improved the isolation yield ($46.8 \pm 11.25 \mu\text{g}\cdot\text{mg}^{-1}$). The reactivity of Roy **1** was explored to prepare new bioactive esters. Consequently, a new (**4**) and three known (**2**, **3**, and **5**) ester derivatives were prepared. Considering the stability study, compounds **1**, **2**, and **3** were evaluated and results indicate that all of them were completely water stable (concentration of 0.1 mM, pH 7.4, and 37°C, for 10 days). Moreover, **1**_NPs were successfully synthesized and exhibit promising physicochemical characteristics and an impressive 74.9% drug conjugation efficiency. Additionally, natural **1**, derivatives **2-5**, and **1**_NPs system exhibit significant activity against the aggressive breast cancer cell line, MDA-MB-231. These findings represent a significant advancement in our ongoing efforts to develop novel therapeutic agents and drug delivery platforms.

Keywords: *Plectranthus*; royleanone; derivatives; stability; antitumoral activity; nanosystem




Introduction



PKC activation



Plectranthus
spp.




7 α -acetoxy-6 β -
hydroxyroyleanone
(Roy 1)




Protein kinase C (PKC)


- ❖ Associated with proliferation, migration, invasion, tumorigenesis, and metastasis
- ❖ Target of many natural products:



Phorbol Esters



Bryostatins



Staurosporine Analogues

Breast cancer therapy: PKC- α activation

Breast cancer caused 685 000 deaths globally in 2020.

Colon cancer therapy: PKC- δ activation

Colorectal cancer is the third most common cancer worldwide.




Matias D, Bessa C, Simões MF, Reis CP, Saraiva L, Rijo P. Natural Products as Lead Protein Kinase C Modulators for Cancer Therapy, in: Atta-ur-Rahman (Ed.), Studies in Natural Products Chemistry, 2016, pp. 45–79.

<https://www.who.int/>



Plectranthus genus

Includes more than 300 species



Basil



Rosemary



Mint



Oregano



Plants obtained from
South Africa and
cultured in Portugal
(Instituto Superior de
Agronomia de Lisboa)

Ladeiras D, Monteiro CM, Pereira F, Reis CP, Afonso CAM, Rijo P. (2016) *Curr Pharm Des*, 22(12), 1682–1714.

Rice LJ, Brits GJ, Potgieter CJ, Van Staden J (2011) *S Afr J Bot* 77: 947-959.

Lukhoba CW, Simmonds MSJ, Paton AJ (2006) *J Ethnopharmacol* 103:1-24.



Plectranthus genus

Current uses:

- Ornamental
- Ethnobotanical
- Household



P. ecklonii

- Unusual applications:**
- P. ciliatus* → Used to wash clothes
 - P. hadiensis* → Fish poison; Charm
 - P. laxiflorus* → Mosquito repellent
 - P. neochilus* → Air purifier
 - P. unguentarius* → Pomade


Food and Food additives:

Nine species reported to be edible and three used as food additives



P. esculentus ⁷


P. grandidentatus Gürke



7 α -acetoxy-6 β -hydroxyroyleanone (Roy 1)



Cytotoxic abietane diterpenes




Roy (1)

Poorly water-soluble
compounds



Nanotechnology:

- Drug solubility
- Targeted delivery



Self-assembly nanosystem:
low cytotoxicity on Vero-E6
cells; may act as a prodrug



Objectives









**Enhance cytotoxic activity of Roy 1 for
anticancer therapy**




Methodology

- ❖ Extraction and isolation
- ❖ Reactivity study
- ❖ Stability study
- ❖ Nanoparticles synthesis
- ❖ Effect on triple negative human breast cancer cell lines






Results and discussion





Roy Reactivity study

Optimization of Roy esterification:




- ❖ Amount of reagent
- ❖ Amount of pyridine
- ❖ Base
- ❖ Temperature
- ❖ Time
- ❖ Work up



Roy Reactivity study



Entry	Reagent / eq	Pyridine (mL)	Temp (°C)	Time (min)	Product/ yield (%)
1	Benzoyl Chloride 15	catalytic	Rt	60	2 69 %
2	Benzoyl Chloride 4	catalytic	0	60	2 58 %
3	Benzoyl Chloride 100	1	50	120	3 28 %
4	Benzoyl Chloride 100	0.5	50	Overnight	3 79 %
5	Acetic Anhydride 1	0.5	Rt	15	4 77 %
6	Acetic Anhydride 8	0.5	0	15	4 86 %
7	Acetic Anhydride 100	1	50	Overnight	5 48 %




- ❖ 12-OH → Mild conditions
- ❖ Both 12 and 6-OH → 50°C, overnight, pyridine as solvent




Stability study



1



3



2



❖ 2 and 20 also displayed stability in aqueous medium



Synthesis of Nanoparticles (NPs)

NPs / Concentration	Size (nm)	PI	ZP	Loading efficiency (%)
1 NPs 0.02 mM	50.17	0.244	-8.02	-
1 _NPs 0.1mM	209.13	0.283	-3.10	74.9%
1 _NPs 5mM	53.99	0.355	-8.71	22.6%

- ❖ Promising physicochemical characteristics
- ❖ 75% loading efficiency



- ❖ **1** and **1**_NPs cytotoxic against breast cancer cell line MDA-MB-231



The 9th International Electronic Conference on Medicinal Chemistry

01-30 November 2023 | Online



Conclusions






P. grandidentatus

Phytochemistry:


- ❖ Extraction yield of 2.3 % (w/w)
- ❖ 46.8 $\mu\text{g}\cdot\text{mg}^{-1}$ Roy **1** in extract → Optimization of the ultrasound acetonic extraction
- ❖ Isolation of 1.0 g of Roy **1** for hemi-synthesis



Optimization of esterification conditions:

- ❖ 12-OH seems the most reactive
- ❖ For both positions derivatization, high temperature (50 °C), excess of reagents, and higher reaction time

Nanoformulation:



- ❖ **1**_NPs system exhibit promising physicochemical characteristics and 75 % drug conjugation efficiency
- ❖ **1** and **1**_NPs cytotoxic against aggressive breast cancer cell line MDA-MB-231.



The 9th International Electronic Conference on Medicinal Chemistry

01–30 November 2023 | Online



Acknowledgment

Support for this work was provided by FCT through PhD grant SFRH/BD/137671/2021.



Supervisor
Patrícia Rijo

CBIOS-Scientific Director
for Communication and
External Relations.

Co-Supervisor

Carlos A. M. Afonso

Full Professor at Faculty of Pharmacy, University of Lisbon

Lucilia Saraiva

LAQV/REQUIMTE, Laboratório de Microbiologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, U. do Porto, Portugal

Dr. Mattia Mori,
Dr. Daniel Santos
Dr. Ricardo Ferreira
Dr. Alfonso T. García-Sosa
Dr. Catarina Reis
Dr. Ana Vieira
Dr. Catarina Leite
Dr. Milica Pesic
Dr. Ana Gasparovic

